Hassan Rakhsh-Khorshid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hassan Rakhsh-Khorshid has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hilda Samimi
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Vahid Haghpanah
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Adrienne M. Gorman
Apoptosis Research Centre, School of Biological and Chemical Sciences University of Galway Galway Ireland
1 shared publication - Afshin Samali
Apoptosis Research Centre, School of Biological and Chemical Sciences University of Galway Galway Ireland
1 shared publication Alessandro Annibaldi
Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
1 shared publicationAna Beatriz Varanda
Cell death, inflammation and immunity laboratory, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany
1 shared publication
Latest Publications
- 26 September 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-8
Immunohistochemical analysis reveals increased active GSK3 and inactive PP2A levels in anaplastic thyroid cancer
Objectives Anaplastic thyroid carcinoma (ATC) is a lethal subtype of thyroid cancer with a poor prognosis. Due to the lack of promising treatment opportunities for ATC, gaining a better understanding of the molecular mechanisms underlying tumorigenesis seems crucial. Here, we focused on two major players in the Wnt signaling pathway. Methods The expression of PP2A and GSK3α/β proteins was studied in 12 ATC and 15 goiter formalin-fixed paraffin-embedded tissue samples using immunohistochemistry. The intensity of nuclear staining in tumor cells, as well as the total scores of protein expression, were calculated. Results The expression of inactive PP2A and active GSK3α/β proteins was negative in all control (goiter) samples. Both proteins were expressed in all ATC samples at different levels. Notably, eight samples represented strong expression (percentage = 100; total score = 300) of both proteins. The average total score staining was 210.3 for the phosphorylated and active form of GSK3α/β (Y279/216) and 274.5 for phosphorylated PP2A at Y307 and its inactive form. For features such as age, gender, greatest diameter of tumors, as well as PP2A and GSK3α/β total staining scores, no significant differences were observed between metastatic and nonmetastatic cases. Similarly, no association was demonstrated between metastasis with demographic and tumor characteristics. Conclusions The current study investigated the expression of PP2A and GSK3α/β, two key proteins in the Wnt signaling pathway, in ATC tissue samples. Although this study highlights the importance of PP2A and GSK3α/β in ATC, a clear understanding of PP2A and GSK3α/β dysregulation and function in ATC remains to be elucidated.
- 26 September 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-8
Immunohistochemical analysis reveals increased active GSK3 and inactive PP2A levels in anaplastic thyroid cancer
Objectives Anaplastic thyroid carcinoma (ATC) is a lethal subtype of thyroid cancer with a poor prognosis. Due to the lack of promising treatment opportunities for ATC, gaining a better understanding of the molecular mechanisms underlying tumorigenesis seems crucial. Here, we focused on two major players in the Wnt signaling pathway. Methods The expression of PP2A and GSK3α/β proteins was studied in 12 ATC and 15 goiter formalin-fixed paraffin-embedded tissue samples using immunohistochemistry. The intensity of nuclear staining in tumor cells, as well as the total scores of protein expression, were calculated. Results The expression of inactive PP2A and active GSK3α/β proteins was negative in all control (goiter) samples. Both proteins were expressed in all ATC samples at different levels. Notably, eight samples represented strong expression (percentage = 100; total score = 300) of both proteins. The average total score staining was 210.3 for the phosphorylated and active form of GSK3α/β (Y279/216) and 274.5 for phosphorylated PP2A at Y307 and its inactive form. For features such as age, gender, greatest diameter of tumors, as well as PP2A and GSK3α/β total staining scores, no significant differences were observed between metastatic and nonmetastatic cases. Similarly, no association was demonstrated between metastasis with demographic and tumor characteristics. Conclusions The current study investigated the expression of PP2A and GSK3α/β, two key proteins in the Wnt signaling pathway, in ATC tissue samples. Although this study highlights the importance of PP2A and GSK3α/β in ATC, a clear understanding of PP2A and GSK3α/β dysregulation and function in ATC remains to be elucidated.
- Open Access
- 23 May 2024
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 31 (7) , 897-909
The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo
Necroptosis is a caspase-independent modality of cell death implicated in many inflammatory pathologies. The execution of this pathway requires the formation of a cytosolic platform that comprises RIPK1 and RIPK3 which, in turn, mediates the phosphorylation of the pseudokinase MLKL (S345 in mouse). The activation of this executioner is followed by its oligomerisation and accumulation at the plasma-membrane where it leads to cell death via plasma-membrane destabilisation and consequent permeabilisation. While the biochemical and cellular characterisation of these events have been amply investigated, the study of necroptosis involvement in vivo in animal models is currently limited to the use of Mlkl−/− or Ripk3−/− mice. Yet, even in many of the models in which the involvement of necroptosis in disease aetiology has been genetically demonstrated, the fundamental in vivo characterisation regarding the question as to which tissue(s) and specific cell type(s) therein is/are affected by the pathogenic necroptotic death are missing. Here, we describe and validate an immunohistochemistry and immunofluorescence-based method to reliably detect the phosphorylation of mouse MLKL at serine 345 (pMLKL-S345). We first validate the method using tissues derived from mice in which Caspase-8 (Casp8) or FADD are specifically deleted from keratinocytes, or intestinal epithelial cells, respectively. We next demonstrate the presence of necroptotic activation in the lungs of SARS-CoV-infected mice and in the skin and spleen of mice bearing a Sharpin inactivating mutation. Finally, we exclude necroptosis occurrence in the intestines of mice subjected to TNF-induced septic shock. Importantly, by directly comparing the staining of pMLKL-345 with that of cleaved Caspase-3 staining in some of these models, we identify spatio-temporal and functional differences between necroptosis and apoptosis supporting a role of RIPK3 in inflammation independently of MLKL versus the role of RIPK3 in activation of necroptosis.
- 23 May 2024
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 31 (7) , 897-909
Open AccessThe importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo
Necroptosis is a caspase-independent modality of cell death implicated in many inflammatory pathologies. The execution of this pathway requires the formation of a cytosolic platform that comprises RIPK1 and RIPK3 which, in turn, mediates the phosphorylation of the pseudokinase MLKL (S345 in mouse). The activation of this executioner is followed by its oligomerisation and accumulation at the plasma-membrane where it leads to cell death via plasma-membrane destabilisation and consequent permeabilisation. While the biochemical and cellular characterisation of these events have been amply investigated, the study of necroptosis involvement in vivo in animal models is currently limited to the use of Mlkl−/− or Ripk3−/− mice. Yet, even in many of the models in which the involvement of necroptosis in disease aetiology has been genetically demonstrated, the fundamental in vivo characterisation regarding the question as to which tissue(s) and specific cell type(s) therein is/are affected by the pathogenic necroptotic death are missing. Here, we describe and validate an immunohistochemistry and immunofluorescence-based method to reliably detect the phosphorylation of mouse MLKL at serine 345 (pMLKL-S345). We first validate the method using tissues derived from mice in which Caspase-8 (Casp8) or FADD are specifically deleted from keratinocytes, or intestinal epithelial cells, respectively. We next demonstrate the presence of necroptotic activation in the lungs of SARS-CoV-infected mice and in the skin and spleen of mice bearing a Sharpin inactivating mutation. Finally, we exclude necroptosis occurrence in the intestines of mice subjected to TNF-induced septic shock. Importantly, by directly comparing the staining of pMLKL-345 with that of cleaved Caspase-3 staining in some of these models, we identify spatio-temporal and functional differences between necroptosis and apoptosis supporting a role of RIPK3 in inflammation independently of MLKL versus the role of RIPK3 in activation of necroptosis.
- Open Access
- 7 November 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (12) , 1-14
Insights into the structure and function of the RNA ligase RtcB
To be functional, some RNAs require a processing step involving splicing events. Each splicing event necessitates an RNA ligation step. RNA ligation is a process that can be achieved with various intermediaries such as self-catalysing RNAs, 5′–3′ and 3′–5′ RNA ligases. While several types of RNA ligation mechanisms occur in human, RtcB is the only 3′–5′ RNA ligase identified in human cells to date. RtcB RNA ligation activity is well known to be essential for the splicing of XBP1, an essential transcription factor of the unfolded protein response; as well as for the maturation of specific intron-containing tRNAs. As such, RtcB is a core factor in protein synthesis and homeostasis. Taking advantage of the high homology between RtcB orthologues in archaea, bacteria and eukaryotes, this review will provide an introduction to the structure of RtcB and the mechanism of 3′–5′ RNA ligation. This analysis is followed by a description of the mechanisms regulating RtcB activity and localisation, its known partners and its various functions from bacteria to human with a specific focus on human cancer.
- 7 November 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (12) , 1-14
Open AccessInsights into the structure and function of the RNA ligase RtcB
To be functional, some RNAs require a processing step involving splicing events. Each splicing event necessitates an RNA ligation step. RNA ligation is a process that can be achieved with various intermediaries such as self-catalysing RNAs, 5′–3′ and 3′–5′ RNA ligases. While several types of RNA ligation mechanisms occur in human, RtcB is the only 3′–5′ RNA ligase identified in human cells to date. RtcB RNA ligation activity is well known to be essential for the splicing of XBP1, an essential transcription factor of the unfolded protein response; as well as for the maturation of specific intron-containing tRNAs. As such, RtcB is a core factor in protein synthesis and homeostasis. Taking advantage of the high homology between RtcB orthologues in archaea, bacteria and eukaryotes, this review will provide an introduction to the structure of RtcB and the mechanism of 3′–5′ RNA ligation. This analysis is followed by a description of the mechanisms regulating RtcB activity and localisation, its known partners and its various functions from bacteria to human with a specific focus on human cancer.
- Open Access
- 1 September 2023
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 8 (3) , 451-458
Illuminating the role of lncRNAs ROR and MALAT1 in cancer stemness state of anaplastic thyroid cancer: An exploratory study
Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans that accounts for a considerable rate of cancer-associated mortality. Since conventional therapies are lacking sufficient efficacy, new treatment approaches are required. This goal could be achieved through a better understanding of the molecular pathogenesis of ATC. Thyroid tumorigenesis is initiated by a subpopulation of cells known as cancer stem cells (CSCs) with specific markers such as CD133 that confers to processes such as self-renewal and metastasis. Besides, some long non-coding RNAs (lncRNAs) promote tumorigenesis by mediating the aforementioned processes. Here, we designed an exploratory study to investigate the role of lncRNAs ROR and MALAT1 and their related genes in CSC stemness. Using magnetic-activated cell sorting (MACS), the CD133- and CD133+ subpopulations were separated in SW1736 and C643 ATC cell lines. Next, the expression profiles of the CD133 marker, MALAT1, and its associated genes (CCND1, NESTIN, MYBL2, MCL1, IQGAP1), as well as ROR and its related genes (POU5F1, SOX2, NANOG), were explored by qRT-PCR. We found significant up-regulation of ROR, POU5F1, SOX2, NANOG, CD133, MALAT1, IQGAP1, and MCL1 in CD133+ SW1736 cells compared to CD133- cells. As for CD133+ C643 cells, CCND1, IQGAP1, POU5F1, SOX2, NANOG, and NESTIN were significantly up-regulated compared to CD133- cells. This study suggests that these lncRNAs in CD133-positive SW1736 and C643 cells might regulate stemness behaviors in ATC.
- 1 September 2023
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 8 (3) , 451-458
Open AccessIlluminating the role of lncRNAs ROR and MALAT1 in cancer stemness state of anaplastic thyroid cancer: An exploratory study
Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans that accounts for a considerable rate of cancer-associated mortality. Since conventional therapies are lacking sufficient efficacy, new treatment approaches are required. This goal could be achieved through a better understanding of the molecular pathogenesis of ATC. Thyroid tumorigenesis is initiated by a subpopulation of cells known as cancer stem cells (CSCs) with specific markers such as CD133 that confers to processes such as self-renewal and metastasis. Besides, some long non-coding RNAs (lncRNAs) promote tumorigenesis by mediating the aforementioned processes. Here, we designed an exploratory study to investigate the role of lncRNAs ROR and MALAT1 and their related genes in CSC stemness. Using magnetic-activated cell sorting (MACS), the CD133- and CD133+ subpopulations were separated in SW1736 and C643 ATC cell lines. Next, the expression profiles of the CD133 marker, MALAT1, and its associated genes (CCND1, NESTIN, MYBL2, MCL1, IQGAP1), as well as ROR and its related genes (POU5F1, SOX2, NANOG), were explored by qRT-PCR. We found significant up-regulation of ROR, POU5F1, SOX2, NANOG, CD133, MALAT1, IQGAP1, and MCL1 in CD133+ SW1736 cells compared to CD133- cells. As for CD133+ C643 cells, CCND1, IQGAP1, POU5F1, SOX2, NANOG, and NESTIN were significantly up-regulated compared to CD133- cells. This study suggests that these lncRNAs in CD133-positive SW1736 and C643 cells might regulate stemness behaviors in ATC.